World's Best Scientists 2026 revealed!
Matthew J. Maurer

Matthew J. Maurer

D-Index & Metrics

Medicine

D-Index
91
Citations
37542
World Ranking
11603
National Ranking
5954

Matthew J. Maurer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Matthew J. Maurer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 903 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Matthew J. Maurer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Matthew J. Maurer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Matthew J. Maurer is affiliated with the Mayo Clinic in the United States and has a primary focus on medicine, contributing extensively across various subfields including pathology and forensic medicine, molecular biology, cardiology and cardiovascular medicine, oncology, and genetics.

The areas of research that define Maurer's career involve lymphoma diagnosis and treatment, amyloidosis with an emphasis on diagnosis, treatment, and outcomes, parathyroid disorders and treatments, chronic lymphocytic leukemia research, cardiomyopathy and myosin studies, CAR-T cell therapy research, and cardiovascular function and risk factors.

They have published in a variety of prominent scientific venues, with frequent contributions to:

  • Blood
  • Journal of the American College of Cardiology
  • Circulation
  • Journal of Cardiac Failure
  • Hematological Oncology

Some recent papers associated with Matthew J. Maurer's field of interest include:

  • "Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial", 2020, The Lancet
  • "Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases", 2021, European Heart Journal
  • "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis", 2023, Journal of the American College of Cardiology
  • "Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases", 2021, European Journal of Heart Failure
  • "ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging", 2021, Circulation Cardiovascular Imaging

Matthew J. Maurer has collaborated regularly with several frequently co-authoring scientists including:

  • James R. Cerhan
  • Thomas M. Habermann
  • Brian K. Link
  • Grzegorz S. Nowakowski
  • Yucai Wang

This body of work reflects a broad and interdisciplinary engagement with medical research, particularly in the overlap between cardiovascular medicine and hematologic malignancies. Their contributions span diagnostic, therapeutic, and consensus guideline approaches contributing to contemporary medical knowledge within multiple overlapping domains of medicine.

Best Publications

  • Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

    Mathew S. Maurer;Jeffrey H. Schwartz;Balarama Gundapaneni;Perry M. Elliott

  • Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

    Julian D. Gillmore;Mathew S. Maurer;Rodney H. Falk;Giampaolo Merlini

  • Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

    Michael Crump;Sattva S. Neelapu;Umar Farooq;Eric Van Den Neste

  • Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    Iacopo Olivotto;Artur Oreziak;Roberto Barriales-Villa;Theodore P. Abraham

  • Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

    Evanthia Galanis;Jan C. Buckner;Matthew J. Maurer;Jeffrey I. Kreisberg

  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou

  • Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

    Pablo Garcia-Pavia;Claudio Rapezzi;Yehuda Adler;Michael Arad

  • ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging

    Sharmila Dorbala;Yukio Ando;Sabahat Bokhari;Angela Dispenzieri

  • Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

    Lao H. Saal;Peter Johansson;Karolina Holm;Sofia K. Gruvberger-Saal

  • ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

    Edgardo R. Parrilla Castellar;Elaine S. Jaffe;Jonathan W. Said;Steven H. Swerdlow

  • Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis

    Mathew S. Maurer;Perry Elliott;Raymond Comenzo;Marc Semigran

  • Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

    Evanthia Galanis;Kurt A. Jaeckle;Matthew J. Maurer;Joel M. Reid

  • Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

    Matthew J. Maurer;Hervé Ghesquières;Hervé Ghesquières;Jean Philippe Jais;Thomas E. Witzig

  • Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.

    Adam Castano;Muhammad Haq;David L. Narotsky;Jeff Goldsmith

  • Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

    Brian K. Link;Matthew J. Maurer;Grzegorz S. Nowakowski;Stephen M. Ansell

  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Nancy L. Bartlett;Wyndham H. Wilson;Sin Ho Jung;Eric D. Hsi

  • Multimorbidity in Older Adults With Cardiovascular Disease

    Daniel E. Forman;Mathew S. Maurer;Cynthia Boyd;Ralph Brindis

  • Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

    Frederick L. Ruberg;Mathew S. Maurer;Daniel P. Judge;Steven Zeldenrust

  • ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/ SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis part 2 of 2-diagnostic criteria and appropriate utilization

    Sharmila Dorbala;Yukio Ando;Sabahat Bokhari;Angela Dispenzieri

  • Diastolic heart failure.

    Mathew S Maurer;Milton Packer;Daniel Burkhoff

Frequent Co-Authors

James R. Cerhan
James R. Cerhan Mayo Clinic
Thomas E. Witzig
Thomas E. Witzig Mayo Clinic
Susan L. Slager
Susan L. Slager Mayo Clinic
Anne J. Novak
Anne J. Novak Mayo Clinic
David J. Inwards
David J. Inwards Mayo Clinic
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center
George J. Weiner
George J. Weiner University of Iowa
Ann L. Oberg
Ann L. Oberg Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA is just one way to start a rewarding healthcare career. Today’s students have many alternative and online pathways to prepare for roles in healthcare and related fields. For example, those interested in nursing can consider schools that help you become an lpn school without teas test requirements, making entry into the profession more accessible.

If you are interested in healthcare leadership, consider enrolling in an accelerated healthcare administration degree online. This allows you to fast-track your education and move into administrative or management roles sooner.

Registered Nurses seeking career advancement can find specialized rn to fnp bridge programs that help bridge the gap between clinical nursing and advanced practice roles, such as Family Nurse Practitioner.

For those passionate about wellness and preventive care, pursuing one of the best online nutrition programs provides the knowledge to support healthier communities. These flexible online options give aspiring healthcare professionals a variety of career starting points beyond the traditional medical school route.

Best Scientists Citing Matthew J. Maurer

Trending Scientists

Recently Published Articles